Altamira Therapeutics
CYTO

$0.7490

0.13%

Market Cap: $2.42M

About: Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.

Employees: 12

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

33% more funds holding

Funds holding: 3 [Q1] → 4 (+1) [Q2]

0.01% more ownership

Funds ownership: 0.11% [Q1] → 0.12% (+0.01%) [Q2]

15% less capital invested

Capital invested by funds: $3.47K [Q1] → $2.95K (-$515) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CYTO.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CYTO published over the past 30 days

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the closing of its previously announced public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant. The Series A-1 common warrants have an exercise price of $0.72 per share, are immediately exercisable upon issuance and expire on the earlier of the eighteen-month anniversary of the initial issuance date or 60 days following the date the Company publicly announces positive biodistribution data for AM-401 or AM-411 nanoparticles. The Series A-2 common warrants have an exercise price of $0.72 per share, are immediately exercisable upon issuance and expire on the earlier of the five-year anniversary of the initial issuance date or six months following the date the Company publicly announces the entry into one or more agreements relating to the further development and commercialization for AM-401 or AM-411, provided at least one such agreement covers a territory that includes all or a part of the European Union or the United States.

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the pricing of a public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant. The Series A-1 common warrants will have an exercise price of $0.72 per share, will be immediately exercisable upon issuance and will expire on the earlier of the eighteen-month anniversary of the initial issuance date or 60 days following the date the Company publicly announces positive biodistribution data for AM-401 or AM-411 nanoparticles. The Series A-2 common warrants will have an exercise price of $0.72 per share, will be immediately exercisable upon issuance and will expire on the earlier of the five-year anniversary of the initial issuance date or six months following the date the Company publicly announces the entry into one or more agreements relating to the further development and commercialization for AM-401 or AM-411, provided at least one such agreement covers a territory that includes all or a part of the European Union or the United States. The closing of the offering is expected to occur on or about September 19, 2024, subject to the satisfaction of customary closing conditions.

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held virtually and in person on September 9-11, 2024, at Lotte New York Palace Hotel in New York City.

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on Altamira Therapeutics Ltd. (NASDAQ: CYTO). The update note includes detailed information on Altamira Therapeutic's management commentary, recent developments, outlook, and risks.

REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its Norwegian partner Pharma Nordic AS (“Pharma Nordic”) to extend the territory covered by their exclusive distribution agreement for Bentrio® to Sweden and Denmark. Following the successful launch in Norway earlier this year, Pharma Nordic intends to introduce the Bentrio nasal spray for the prevention and treatment of allergic rhinitis in these two additional Scandinavian countries next year.

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Altamira Medica Ltd. (“Altamira” or the “Company”), an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), today announced that its preservative-free, drug-free Bentrio® nasal spray for allergic rhinitis was tested successfully for the absence of more than 230 prohibited substances listed by the World Anti-Doping Agency (WADA). This finding further confirms Bentrio's suitability for athletes who must comply with antidoping regulations but at the same time need to protect themselves against airborne allergens or other particles.

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of a peer-reviewed article in Nature Immunology highlighting the important role of the Zbtb46 gene in the control of tumor growth and demonstrating a significant reduction in tumor growth in vivo through treatment with Zbtb46 mRNA delivered with Altamira's SemaPhore™ nanoparticle technology.1 The treatment effect was potentiated when combined with anti-PD1 immune checkpoint inhibition, inducing long-term remission and promoting immunological memory. The research was conducted by a group around Professor Kyunghee Choi of the Pathology & Immunology Department of Washington University School of Medicine (St. Louis, MO).

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the preprint publication of a study demonstrating effective treatment of abdominal aortic aneurysm (AAA) in an animal model.1 The study was conducted by a research group from Washington University, St. Louis MO, and the University of South Florida, Tampa FL. It showed that treatment with SOD2 mRNA delivered systemically with peptide-based nanoparticles (SemaPhore™ by Altamira) to AAA mice resulted in a significant reduction in aorta dilation (p

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today highlighted the publication of an article describing the rationale for and use of betahistine in the treatment of residual dizziness following standard of care physical repositioning procedures for benign paroxysmal positional vertigo (BPPV). The peer reviewed article was published by an international group of medical and scientific experts in vestibular disorders in the journal Frontiers in Neurology1 and reviews the potential causes of residual dizziness, which has been reported to occur in 31-61% of patients, and available treatment options.

Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

Altamira Therapeutics Provides Business Update

Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update related to its RNA delivery platform, partnering of its legacy assets, corporate structuring and financial reporting.

Altamira Therapeutics Provides Business Update

See News Rankings